

RealRate

PHARMACEUTICAL 2019

## Xenon Pharmaceuticals Inc. Rank 77 of 363



🖁 XENON







PHARMACEUTICAL 2019



Xenon Pharmaceuticals Inc. Rank 77 of 363



The relative strengths and weaknesses of Xenon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenon Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 112% points. The greatest weakness of Xenon Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 202%, being 165% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	121,437
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,119
Liabilities, Non-Current	15,014
Other Assets	0
Other Compr. Net Income	0
Other Expenses	7,394
Other Liabilities	0
Other Net Income	4,913
Other Revenues	0
Property and Equipment	991
Research and Development	23,634
Selling, General and Administrative Expense	8,382

Output Variable	Value in 1000 USD
Assets	122,428
Liabilities	19,133
Expenses	39,410
Revenues	0
Stockholders Equity	103,295
Net Income	-34,497
Comprehensive Net Income	-34,497
Economic Capital Ratio	202%

